CHRS

CHS-131

Nonalcoholic steatohepatitis (NASH)

Phase 2

Exp Date

TBD

Amp Volatility Score

Catalyst Info & Data Links

TITLE: CHS-131 in  Nonalcoholic steatohepatitis (NASH)


WHAT IS THE CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA/EVENTS

PRESS RELEASE

COMPETITORS

MARKET

  • ~20 percent of people with NAFLD have NASH

  • Between 30 and 40 percent of adults in the United States have NAFLD. 

  • ~ 3 to 12 percent of adults in the United States have NASH


MECHANISM OF ACTION / RATIONALE

  • CHS-131, a first-in-class, non-immunosuppressive, highly-selective PPARγ agonist that crosses the blood-brain-barrier, has potent anti-inflammatory activity and is clinically effective in EAE.


Updated by HC

#CHRS, #CHS-131, # Nonalcoholic_steatohepatitis, #NASH

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon